Who
Mark L. Baum
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Harrow; Director, Eton Pharmaceuticals; Director, Ideal Power; Chief Executive Officer, Shrink Nanotechnologies; Other, Quest Oil.
In numbers
- Trades disclosed
- 106
- Buys
- 10
- Sells
- 9
- Bought
- $1.6M
- Sold
- $433K
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 7 Jun 2006
- Last trade
- 14 May 2026
- Last filed
- 15 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 May 2026filed 15 May 2026 | HROW HarrowPharmaceuticals | SEC FORM 4 Bought | $302K10,000 at $30.20 | filing |
| 14 May 2026filed 15 May 2026 | HROW HarrowPharmaceuticals | SEC FORM 4 Bought | $302K10,000 at $30.20 | filing |
| 12 Dec 2025filed 16 Dec 2025 | HROW Harrowoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —180,000 at $0.00 | filing |
| 12 Dec 2025filed 16 Dec 2025 | HROW HarrowPharmaceuticals | SEC FORM 4 Code M | $711K180,000 at $3.95 | filing |
| 12 Dec 2025filed 16 Dec 2025 | HROW HarrowPharmaceuticals | SEC FORM 4 Code F | $3.8M79,994 at $47.06 | filing |
| 21 Jul 2025filed 23 Jul 2025 | HROW HarrowPharmaceuticals | SEC FORM 4 Code M | $4.7M600,000 at $7.87 | filing |
| 21 Jul 2025filed 23 Jul 2025 | HROW HarrowPharmaceuticals | SEC FORM 4 Code F | $11.6M313,338 at $37.08 | filing |
| 1 Jul 2025filed 1 Jul 2025 | HROW Harrowoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —889,500 at $0.00 | filing |
| 7 Apr 2025filed 7 Apr 2025 | HROW HarrowPharmaceuticals | SEC FORM 4 Code F | $6.9M300,363 at $23.09 | filing |
| 3 Apr 2025filed 7 Apr 2025 | HROW Harrowoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —762,300 at $0.00 | filing |
| 3 Apr 2025filed 7 Apr 2025 | HROW HarrowPharmaceuticals | SEC FORM 4 Code M | —762,300 at $0.00 | filing |
| 22 Mar 2024filed 25 Mar 2024 | HROW HarrowPharmaceuticals | SEC FORM 4 Bought | $104K9,000 at $11.59 | filing |
| 20 Feb 2024filed 21 Feb 2024 | HROW Harrowoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —150,000 at $0.00 | filing |
| 20 Feb 2024filed 21 Feb 2024 | HROW HarrowPharmaceuticals | SEC FORM 4 Code M | $1.6M150,000 at $10.67 | filing |
| 20 Feb 2024filed 21 Feb 2024 | HROW HarrowPharmaceuticals | SEC FORM 4 Code M | $638K59,836 at $10.67 | filing |
| 7 Feb 2024filed 8 Feb 2024 | HROW Harrowoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —15,400 at $0.00 | filing |
| 7 Feb 2024filed 8 Feb 2024 | HROW HarrowPharmaceuticals | SEC FORM 4 Code M | $119K15,400 at $7.71 | filing |
| 16 Nov 2023filed 16 Nov 2023 | HROW HarrowPharmaceuticals | SEC FORM 4 Bought | $61K7,500 at $8.11 | filing |
| 14 Aug 2023filed 15 Aug 2023 | HROW HarrowPharmaceuticals | SEC FORM 4 Bought | $99K5,800 at $17.05 | filing |
| 18 Jul 2023filed 20 Jul 2023 | HROW Harrowoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —762,300 at $0.00 | filing |
News
Comparing Harrow (NASDAQ:HROW) & Teva Pharmaceutical Industries (NYSE:TEVA)HROW · tickerreport.com · 16 Oct 2026
0 headlines in the last 90 days name Mark L. Baum; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.